Inventor · disambiguated record
John King-Underwood
Also filed as: KING-UNDERWOOD JOHN
41 granted patents·4 pending applications·514 citations·filing 2004–2023
98Inventor score
Files withRESPIVERT LTD31ITO KAZUHIRO6KING-UNDERWOOD JOHN4FYFE MATTHEW COLIN THOR1JAGUAHR THERAPEUTICS PTE LTD1
Top patents by PatentIndex Score
45 records- 0197US9624196B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2016·Granted Apr 18, 2017·15 cites·5 claims
- 0297US9108950B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Aug 18, 2015·38 cites·13 claims
- 0396US9447076B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2015·Granted Sep 20, 2016·16 cites·18 claims
- 0496US8642773B2P38MAP kinase inhibitorITO KAZUHIRO·Filed 2010·Granted Feb 4, 2014·44 cites·4 claims
- 0596US8293771B2p38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 23, 2012·49 cites·9 claims
- 0696US8293748B2p38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 23, 2012·47 cites·19 claims
- 0795US8618140B2P38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2012·Granted Dec 31, 2013·41 cites·20 claims
- 0895US8299073B2P38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 30, 2012·50 cites·19 claims
- 0995US8299074B2P38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 30, 2012·48 cites·17 claims
- 1094US8975285B2P38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Mar 10, 2015·26 cites·3 claims
- 1192US10738032B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Aug 11, 2020·3 cites·24 claims
- 1292US9475796B21-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Oct 25, 2016·12 cites·14 claims
- 1392US9249125B2Pyrazole derivatives as p38 MAP inhibitorsRESPIVERT LTD·Filed 2013·Granted Feb 2, 2016·30 cites·12 claims
- 1492US9024041B2P38 MAP kinase inhibitorsKING-UNDERWOOD JOHN·Filed 2011·Granted May 5, 2015·27 cites·28 claims
- 1591US10266519B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Apr 23, 2019·6 cites·11 claims
- 1689US9724347B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2016·Granted Aug 8, 2017·5 cites·17 claims
- 1788US9850231B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Dec 26, 2017·5 cites·8 claims
- 1886US10238658B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2018·Granted Mar 26, 2019·3 cites·19 claims
- 1985US9242960B2P38MAP kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Jan 26, 2016·6 cites·6 claims
- 2085US8741909B2PI3 kinase inhibitorsKING-UNDERWOOD JOHN·Filed 2010·Granted Jun 3, 2014·7 cites·25 claims
- 2184US9260410B2P38 MAP kinase inhibitorsKING-UNDERWOOD JOHN·Filed 2011·Granted Feb 16, 2016·7 cites·10 claims
- 2283US10294216B2Pyrazolyl ureas as kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted May 21, 2019·1 cites·13 claims
- 2383US9993478B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 12, 2018·2 cites·19 claims
- 2483US9701670B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Jul 11, 2017·10 cites·18 claims
- 2580US2024343711A11-pyrazolyl-3- (4- ((2 -anilinopyrimidin- 4 - yl) oxy) napththalen- i - yl) ureas as p38 mapkinase inhibitorsRESPIVERT LTD·Filed 2023·Application pending·0 cites
- 2678US9321773B2CompoundsRESPIVERT LTD·Filed 2014·Granted Apr 26, 2016·2 cites·1 claims
- 2776US11634406B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2020·Granted Apr 25, 2023·0 cites·10 claims
- 2876US11142515B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 12, 2021·0 cites·9 claims
- 2976US9884845B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Feb 6, 2018·1 cites·17 claims
- 3074US9834560B2CompoundsRESPIVERT LTD·Filed 2016·Granted Dec 5, 2017·1 cites·21 claims
- 3174US8207147B2Heterocyclic derivatives as GPCR receptor agonistsFYFE MATTHEW COLIN THOR·Filed 2004·Granted Jun 26, 2012·10 cites·11 claims
- 3273US9340545B2Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted May 17, 2016·1 cites·8 claims
- 3372US9771354B2Pyrazole p38 map kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Sep 26, 2017·1 cites·31 claims
- 3470US10815217B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2018·Granted Oct 27, 2020·0 cites·13 claims
- 3569US10813932B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 27, 2020·0 cites·18 claims
- 3668US10045980B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2017·Granted Aug 14, 2018·0 cites·13 claims
- 3761US2025188069A1Compounds and methods for degrading casein kinase 1 alphaPIN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3859US2018118754A1CompoundsRESPIVERT LTD·Filed 2017·Application pending·0 cites
- 3958US10028959B2Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jul 24, 2018·0 cites·5 claims
- 4055US10000471B2Pyrazole P38 map kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 19, 2018·0 cites·33 claims
- 4155US9637494B2Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted May 2, 2017·0 cites·4 claims
- 4250US2013029990A1Pyrazole p38 map kinase inhibitorsKING-UNDERWOOD JOHN·Filed 2011·Application pending·0 cites
- 4347US10144721B2P38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Dec 4, 2018·0 cites·13 claims
- 4445US12221439B2Tetrahydropyridopyrimidine derivatives as AhR modulatorsJAGUAHR THERAPEUTICS PTE LTD·Filed 2019·Granted Feb 11, 2025·0 cites·20 claims
- 4536US10160772B25,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivativesPULMOCIDE LTD·Filed 2015·Granted Dec 25, 2018·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when John King-Underwood files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →